The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic ...

Millions of Americans suffer from dry eye disease, an often-overlooked condition that can significantly impact daily life. In ...

Spun off from Novartis in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of ...

I live with lacrimal gland failure, corneal neuralgia, and meibomian gland dysfunction—also known as dry eye. These diseases ...

Dr. Noaman Sanni, a leading ophthalmologist and CEO of Center for Sight New York, has witnessed significant patient and ...

The FDA approved Tryptyr to treat the signs and symptoms of dry eye disease, according to a press release from Alcon. Tryptyr ...

The FDA has approved Tryptyr (acoltremon) as the first TRPM8-targeting eye drop for dry eye disease, stimulating natural tear ...

Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms ...

Dry eye syndrome, a condition affecting millions of Americans each year, continues to present a frustrating challenge for ...

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S.

Dry eyes can sometimes cause headaches, likely because of eye strain or shared inflammatory and nerve pathways.